has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Online First from The Oncologist
- Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
- Computed Tomography‐Based Body Composition Is Not Consistently Associated with Outcome in Older Patients with Colorectal Cancer
- Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants
- Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
- Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
Clinical Trials Results from The Oncologist
- Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study [CLINICAL TRIAL RESULTS]
- Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer [CLINICAL TRIAL RESULTS]
- Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study [CLINICAL TRIAL RESULTS]
- A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor [CLINICAL TRIAL RESULTS]
- A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors [CLINICAL TRIAL RESULTS]